is bupropion contraindicated in people with current or past anorexia or bulimia?
“Bupropion is contraindicated in patients with current or prior and erectionerbosa, or bulimian herbosa.”
a host, a psychiatry resident said on PsychEd: Educational Psychiatry Podcast, 2026-10-01, at 12:29. hear it in context →
the episode: PsychEd Shorts 17: Medical Considerations in Eating Disorders (at 12:29). we link the show's own page; we do not re-host audio.
first, the part that holds
the resident has it right. us bupropion labels for both the immediate-release and extended-release tablets list a current or prior diagnosis of bulimia or anorexia nervosa as a contraindication, and the reason given is a higher rate of seizures.
what we found when we went and looked
we read two current us labels on dailymed: an immediate-release tablet label (revised march 2023) and an extended-release (sr) tablet label (revised january 2026). both say in section 4 that bupropion is "contraindicated in patients with a current or prior diagnosis of bulimia or anorexia nervosa," and both repeat this in the seizure warning. the extended-release label says the reason is that "a higher incidence of seizures was observed in such patients treated with the immediate-release formulation." the trial usually cited for this is a 1988 placebo-controlled study in 81 people with bulimia who were not depressed. 4 of the 55 people on bupropion (about 7%) had grand mal seizures, and the authors advised against giving bupropion alone to people with bulimia.
assertion by assertion
| assertion | verdict | what the record says |
|---|---|---|
| bupropion is contraindicated in patients with a current or prior diagnosis of bulimia nervosa | confirmed | both the immediate-release label and the extended-release (sr) label list a "current or prior diagnosis of bulimia" in section 4 and again in the seizure warning. we read two generic labels, not every formulation sold, but the extended-release label applies the same restriction to a different formulation. [1][2] |
| bupropion is contraindicated in patients with a current or prior diagnosis of anorexia nervosa | confirmed | the same section 4 sentence in both labels names anorexia nervosa alongside bulimia, and the word "prior" means a past diagnosis counts, not only a current one. neither label gives a separate seizure rate for anorexia. [1][2] |
| the contraindication exists because of seizure risk, based on trial data in people with bulimia | confirmed | the extended-release label ties the contraindication to a higher seizure incidence seen with the immediate-release formulation. in the 1988 multicenter trial, 4 of 55 people with bulimia on bupropion (about 7%) had grand mal seizures, which the authors called far higher than in earlier studies of the drug. that is a small trial with an uncontrolled comparison to other studies. [1][3] |
| the anorexia part of the contraindication rests on its own published seizure data | unverifiable | the labels group anorexia with bulimia and give no numbers for either. the trial we read enrolled only people with bulimia. we did not find or read a primary source that measures seizure rates on bupropion in people with anorexia specifically. [1][2][3] |
both directions
for the speaker: the wording on the podcast matches the label almost word for word: "current or prior diagnosis," and both eating disorders are named. it is a contraindication in section 4 of the label, not a softer warning or precaution, and it appears in both the immediate-release and extended-release labels we read. the 1988 trial gives a concrete source for the seizure concern: 4 grand mal seizures among 55 people with bulimia on the drug, which led the authors to recommend against using it alone in this group.
against: nothing in the record contradicts the statement as made. the one gap is in the evidence behind it, not in what was said. the trial data we found are in bulimia only, and the labels extend the restriction to anorexia without giving a separate number. the labels also do not quantify the "higher incidence" anywhere. the roughly 7% figure comes from one small trial from 1988 that used the immediate-release formulation at the doses of that era, and it has no direct comparison group for seizure rates.
what this cannot say
we read two generic us labels on dailymed, not every bupropion product. we did not check combination products, smoking-cessation labeling, or labels outside the us (ema, mhra). we read the 1988 trial as an abstract only, so we cannot report doses, timing of the seizures, or any purging-related electrolyte problems in the people who had seizures. a contraindication is a regulatory label statement. it does not tell you how a prescriber weighs an individual case, and nothing here is advice to start, stop or change a medication.
nothing here is a reason to start, stop or change a medication; those decisions belong with the person taking it and their prescriber.
sources, each one fetched and read
- dailymed (us national library of medicine), bupropion hydrochloride extended-release tablets (sr), prescribing information, revised january 2026 What we read there: section 4: "contraindicated in patients with a current or prior diagnosis of bulimia or anorexia nervosa as a higher incidence of seizures was observed in such patients treated with the immediate-release formulation of bupropion." section 5.3 repeats the contraindication for "current or prior diagnosis of anorexia nervosa or bulimia." Fetched 2026-10-12 (HTTP 200). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f69b322b-93ab-407a-bf25-fe13c6896ca6
- dailymed (us national library of medicine), bupropion hydrochloride tablets (immediate-release), prescribing information, revised march 2023 What we read there: "contraindicated in patients with a current or prior diagnosis of bulimia or anorexia nervosa as a higher incidence of seizures was observed in such patients treated with bupropion hydrochloride tablets." no incidence figure is given. Fetched 2026-10-12 (HTTP 200). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e4100232-a25d-4468-9057-af7e66205154
- horne rl et al., treatment of bulimia with bupropion: a multicenter controlled trial, journal of clinical psychiatry, 1988; pmid 3134343 What we read there: 81 people with bulimia who were not depressed (55 on bupropion, 26 on placebo). the drug was superior to placebo for binge eating and purging, but "four subjects experienced grand mal seizures during treatment with bupropion, a frequency of seizures far higher than observed in previous studies". the authors recommended that "bupropion not be administered alone to bulimic patients." Fetched 2026-10-12 (HTTP 203). https://pubmed.ncbi.nlm.nih.gov/3134343/
speakers are described by role, not named. one sentence is quoted under fair use, with attribution and a link to the original at the timestamp; we do not re-host audio or video. nothing on this page is a reason to start, stop or change a medication. if you have the file behind anything marked unverifiable, the research board is where people can answer. adam